RNAZ: the cash flow

MyFinsight

The latest financial statement is for the quarter ending 2026-03-31.

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Amortization of right-of-use asset	-	0	0	37,731
Non-cash transaction costs	-	6,836,992	-	-
Share-based compensation expense	-	61,865	134,324	289,239
Net loss	-17,785,071	-13,443,110	-4,856,051	-16,361,915
Depreciation	23,936	44,780	4,781	26,885
Non-cash acquired in-process research and development cost	10,426,257	-	-	-
Change in fair value of contingent consideration	-116,000	-1,584,000	-	-
Change in fair value of warrant liabilities	125,348	-398,476	279,161	9,396,636
Due from related parties	-	638	-	-
Prepaid expenses and other current assets	695,656	-911,823	1,026,051	-591,489
Operating lease liability	-	0	0	-38,291
Security deposit	-	0	0	-111,856
Accounts payable and accrued expenses	1,774,088	-43,150	1,402,837	-1,143,146
Deferred grant income	85,262	0	0	-25,408
Grants receivable	-952,460	754,164	22,174	176,122
Deferred tax liability	231,309	226,068	-	-
Net cash used in operating activities	-4,978,067	-8,142,010	-4,083,173	-7,291,046
Cash acquired through the acquisition of polynoma	-	2,224	-	-
Purchase of equipment	-	6,660	-	-
Net cash used in investing activities	-	-4,436	-	-
Proceeds from offering of preferred stock (series b), net of offering costs	-	22,668,324	-	-
Net proceeds from sales of common stock	-	1	0	8,854,797
Payments of deferred offering costs	-	-	455,726	-
Net cash provided by financing activities	-	23,124,051	-455,726	8,854,797
Net change in cash	-4,978,067	14,977,605	-4,538,899	1,563,751
Cash, beginning of period	17,813,521	2,835,916	5,811,064	-
Cash, end of period	12,835,454	17,813,521	2,835,916	-

Unit: Dollar. Numbers labeled with * are estimated quarterly values.